EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)ÄquivalenzstudieMultizentrische Studie

Asundexian versus Apixaban in Patients with Atrial Fibrillation

Jonathan P Piccini, Manesh R Patel, Jan Steffel, Keith Ferdinand, Isabelle C Van Gelder, Andrea M Russo, Chang-Sheng Ma, Shaun G Goodman, Jonas Oldgren, Christopher Hammett, Renato D Lopes, Masaharu Akao und 18 weitere

New England Journal of Medicine · 02.01.2025 · 392 (1) · 23-32

DOI: 10.1056/nejmoa2407105 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 02.01.2025. Verfasst von Jonathan P Piccini und 29 weiteren Autor:innen. Beteiligte Einrichtung: From Duke Clinical Research Institute, Duke University School of Medicine (J.P.P., M.R.P., R.D.L., W.S.J., J. Harrington, S.J.E., F.W.R., J.H.A.), an…. Hauptthemen laut MEDLINE: Anticoagulants, Atrial Fibrillation, Embolism, Hemorrhage. Die Arbeit wurde bisher 181-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsAtrial FibrillationEmbolismHemorrhageStrokeAgedAged, 80 and overFemaleHumansMaleAdministration, OralDouble-Blind MethodFactor Xa InhibitorsHydrocarbons, FluorinatedIntention to Treat AnalysisPyrazolesPyridonesBenzamidesTriazoles

Substanzen

AnticoagulantsapixabanasundexianFactor Xa InhibitorsHydrocarbons, FluorinatedPyrazolesPyridonesBenzamidesTriazoles

Autor:innen und Institutionen

  • From Duke Clinical Research Institute, Duke University School of Medicine (J.P.P., M.R.P., R.D.L., W.S.J., J. Harrington, S.J.E., F.W.R., J.H.A.), and Duke University Medical Center (J.P.P., M.R.P., R.D.L., W.S.J., J. H…

ORCID-Profile: Raffaele De Caterina, Josephine Harrington, Gregory Y H Lip

Förderung

  • Bayer

Zitieren

APA

Piccini, J. P., Patel, M. R., Steffel, J., Ferdinand, K., Van Gelder, I. C., Russo, A. M., Ma, C. S., Goodman, S. G., Oldgren, J., Hammett, C., Lopes, R. D., Akao, M., De Caterina, R., Kirchhof, P., Gorog, D. A., Hemels, M., Rienstra, M., Jones, W. S., Harrington, J., …, & OCEANIC-AF Steering Committee and Investigators (2025). Asundexian versus Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine, 392(1), 23-32. https://doi.org/10.1056/nejmoa2407105

Vancouver

Piccini JP, Patel MR, Steffel J, Ferdinand K, Van Gelder IC, Russo AM, et al. Asundexian versus Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine. 2025;392(1):23-32. doi:10.1056/nejmoa2407105

BibTeX
@article{Piccini2025,
  author = {Piccini, Jonathan P and Patel, Manesh R and Steffel, Jan and Ferdinand, Keith and Van Gelder, Isabelle C and Russo, Andrea M and Ma, Chang-Sheng and Goodman, Shaun G and Oldgren, Jonas and Hammett, Christopher and Lopes, Renato D and Akao, Masaharu and De Caterina, Raffaele and Kirchhof, Paulus and Gorog, Diana A and Hemels, Martin and Rienstra, Michiel and Jones, W Schuyler and Harrington, Josephine and Lip, Gregory Y H and Ellis, Stephen J and Rockhold, Frank W and Neumann, Christoph and Alexander, John H and Viethen, Thomas and Hung, James and Coppolecchia, Rosa and Mundl, Hardi and Caso, Valeria and OCEANIC-AF Steering Committee and Investigators, OCEANIC-AF Steering Committee and Investigators},
  title = {Asundexian versus Apixaban in Patients with Atrial Fibrillation},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {1},
  pages = {23--32},
  doi = {10.1056/nejmoa2407105}
}
Kostenlos starten →